• AUT00206 reduces the ketamine-induced BOLD response in a randomized placebo-controlled Phase Ib trial • Results are highly supportive of the potential for AUT00206 to treat psychiatric disorders such as…
Read More
Stevenage, UK – 18 January 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced that the…
Read More
Collaboration with funding of development activities gives Boehringer Ingelheim exclusive option to purchase certain Autifony assets to treat serious CNS disorders Most advanced compound is in Phase Ib studies, with…
Read More
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced that the U.S. Food and Drug Administration…
Read More
